Effectiveness of palifermin in the prevention of oral mucositis in patients with haematological cancers
Copyright © 2009 SEFH. Published by Elsevier Espana. All rights reserved..
OBJECTIVE: To assess the effectiveness of palifermin for the prevention of oral mucositis in patients with haematological cancers.
METHODS: Retrospective observational study of cohorts of patients with haematological cancer undergoing cytotoxic therapy causing hematopoietic ablation. The main variable assessed was the duration of the oral mucositis. Secondary variables assessed were incidence of mucositis, febrile or septic neutropenia and the administration of opioids and parenteral nutrition.
RESULTS: We included 36 patients in this study, 11 in the group that received palifermin and 25 in the control group. The duration of oral mucositis was 4.6+/-3.1 days (median: 5 days) in the patients treated with palifermin in comparison with 7.4+/-4.0 days (median: 6 days) in patients treated with conventional prophylactic therapy (p<0.05). However, no significant differences were seen in the incidence of mucositis, febrile or septic neutropenia, opioid administration of the use of parenteral nutrition.
CONCLUSIONS: Prophylactic treatment with palifermin reduces the duration of oral mucosities in patients with haematological cancer. Further studies are necessary with larger samples to be able to assess palifermin and its influence on other variables, such as incidence of mucositis, sepsis, febrile neutropenia, etc.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria - 34(2010), 4 vom: 15. Juli, Seite 163-9 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Efectividad de la palifermina en la prevención de la mucositis oral en pacientes oncohematológicos |
|---|
| Beteiligte Personen: |
Ayago Flores, D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
126469-10-1 |
|---|
| Anmerkungen: |
Date Completed 13.01.2011 Date Revised 19.07.2010 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.farma.2009.12.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM199128022 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM199128022 | ||
| 003 | DE-627 | ||
| 005 | 20231223214034.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.farma.2009.12.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0664.xml |
| 035 | |a (DE-627)NLM199128022 | ||
| 035 | |a (NLM)20580585 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Ayago Flores, D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of palifermin in the prevention of oral mucositis in patients with haematological cancers |
| 246 | 3 | 3 | |a Efectividad de la palifermina en la prevención de la mucositis oral en pacientes oncohematológicos |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2011 | ||
| 500 | |a Date Revised 19.07.2010 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2009 SEFH. Published by Elsevier Espana. All rights reserved. | ||
| 520 | |a OBJECTIVE: To assess the effectiveness of palifermin for the prevention of oral mucositis in patients with haematological cancers | ||
| 520 | |a METHODS: Retrospective observational study of cohorts of patients with haematological cancer undergoing cytotoxic therapy causing hematopoietic ablation. The main variable assessed was the duration of the oral mucositis. Secondary variables assessed were incidence of mucositis, febrile or septic neutropenia and the administration of opioids and parenteral nutrition | ||
| 520 | |a RESULTS: We included 36 patients in this study, 11 in the group that received palifermin and 25 in the control group. The duration of oral mucositis was 4.6+/-3.1 days (median: 5 days) in the patients treated with palifermin in comparison with 7.4+/-4.0 days (median: 6 days) in patients treated with conventional prophylactic therapy (p<0.05). However, no significant differences were seen in the incidence of mucositis, febrile or septic neutropenia, opioid administration of the use of parenteral nutrition | ||
| 520 | |a CONCLUSIONS: Prophylactic treatment with palifermin reduces the duration of oral mucosities in patients with haematological cancer. Further studies are necessary with larger samples to be able to assess palifermin and its influence on other variables, such as incidence of mucositis, sepsis, febrile neutropenia, etc | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Narcotics |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factor 7 |2 NLM | |
| 650 | 7 | |a 126469-10-1 |2 NLM | |
| 700 | 1 | |a Ferriols Lisart, R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria |d 1998 |g 34(2010), 4 vom: 15. Juli, Seite 163-9 |w (DE-627)NLM093839022 |x 2171-8695 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2010 |g number:4 |g day:15 |g month:07 |g pages:163-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.farma.2009.12.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2010 |e 4 |b 15 |c 07 |h 163-9 | ||